🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ASCO25 Dr. Charlie Rudin presents interim analysis of DeLLphi-304: randomized phase II study of tarlatamab (DLL3 TCE) vs 2L chemo in #SCLC. Chemo was mostly topotecan; 45% of pts were platinum resistant. Clear OS benefit with HR 0.60 (13.6m vs 8.3m). PFS 4.2 vs 3.7m, HR 0.71.

.Charlie Rudin Dellpi304 RP3 Tarla vs chemo-mono in 2L ES-SCLC Asymptomatic untreated CNS mets allowed. 44% plat resitnt 1o: OS PFS HR 0.61: 3.7 vs 4.2 mo; tail developing OS HR 0.6 at IA1 13.6 vs 8.3mo ORR: 35 vs 20% DOR: 6.9 vs 5.5 Nil new re AEs A new SOC #ASCO25

~13yrs of neoadjuvant adventure comes to positive conclusion (for now)! In NEJM today & presented at #ASCO25 5 yr survival for pts w lung cancer that can be removed by surgery is better with just 3 doses of immunotherapy before the operation! nejm.org/doi/full/10.10… #LCSM 1/

Was so good to see you! Hope to see you soon, congrats on a terrific meeting! ASCO #ASCO25 Amanda Narod Sarah Hopkins

Last day of #ASCO25!! If you’re still in Chicago this morning, please join us for the highlights of the day session!! 📍Hall D1 ASCO MD Anderson Cancer Center

🚨 Don’t miss our educational session today! 📍 E450A, 8 AM CT 🎤 Kaushal Parikh Biagio Ricciuti, MD, PhD ASCO #ASCO25 OncoAlert #LCSM

🔍 Genomics meets the OR in #NSCLC at #ASCO25! Explore how EGFR, ALK, KRAS, RET & more shape perioperative strategies & surgical planning. Precision medicine is rewriting the playbook for early-stage lung cancer Charu Aggarwal, MD, MPH, FASCO Kaushal Parikh

This is going to be a great session with Charu Aggarwal, MD, MPH, FASCO Kaushal Parikh!! Biomarker testing absolutely matters even in early-stage disease for patients with NSCLC! #ASCO25 ASCO

🚨 Don’t miss our educational session today! 📍 E450A, 8 AM CT 🎤 Kaushal Parikh Biagio Ricciuti, MD, PhD ASCO #ASCO25 OncoAlert #LCSM

Great talk by the amazing Charu Aggarwal, MD, MPH, FASCO about definition of curative therapy in patients with "common" AGAs, in other words, EGFR/ALK. We are still trying to understand exactly TKIs are going to fit in patients candidates to surgery. #ASCO25

#ASCO25 ASCO has been incredible - breadth and depth of research presented by Penn Cancer Innovation Penn Medicine - Abramson Cancer Center Penn Medicine Penn Medicine MD Here is a quick recap! tinyurl.com/49yvc65f #LCSM #QoL #AI #FinancialToxicity Ronac Mamtani Lynn Schuchter Melina Marmarelis

🚨If you were not at #ASCO25 for ASCO Highlights today, you must stream Eric K. Singhi, MD excellent presentation! Very informative!

Time to Back to the ward. With more knowledge. More energy. More courage. Thank you #ASCO25 for 5 unforgettable days—full of learning, connection, and hope. See you soon 💙 ASCO OncoAlert #oncology #cancer Toni Choueiri, MD Emre Yekedüz Dana-Farber 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Neeraj Agarwal, MD, FASCO

Thoughtful discussion in our #ASCO25 session on perioperative approaches in #NSCLC, including rare drivers and hard-to-treat genotypes— alongside stellar faculty Charu Aggarwal, MD, MPH, FASCO & Kaushal Parikh. ASCO Dana-Farber News Narjust Florez, MD, FASCO OncoAlert Marcelo Corassa, MD. Dana-Farber

#RapidUpdates from #ASCO25! This is a must listen quick update in #LungCancer w/ Stephen V Liu, MD Narjust Florez, MD, FASCO Patrick Forde IASLC ASCO Penn Medicine - Abramson Cancer Center

In this episode of the IASLC podcast, Lung Cancer Considered, I am joined by Drs. Narjust Florez, MD, FASCO Charu Aggarwal, MD, MPH, FASCO Patrick Forde to discuss the most impactful lung cancer studies from #ASCO25. Available wherever you download podcasts! iaslc.org/iaslc-news/lun…

FDA approves taletrectinib for #ROS1 NSCLC based on TRUST I and TRUST II trials showing 1L RR 85-90% with 63-72% of responses lasting ≥12 months and post TKI, RR 52-62%. Taletrectinib has selectivity over TrkB so should have less neurotoxicity. fda.gov/drugs/resource…

New U.S. FDA accelerated approval: Dato-DXd for EGFR+ NSCLC after prior EGFR therapy + platinum chemo. ▫️n=114, TROPIONLung01&05 ▫️ORR: 45% ▫️DoR: 6.5 mo ⚠️ ILD, ocular AEs, stomatitis, embryo-fetal risk OncoAlert #lcsm

FDA grants accelerated approval for datopotamab deruxtecan, anti-TROP2 ADC, for #EGFR mutant NSCLC after prior TKI and chemotherapy. An active agent, based on TROPION-Lung01 and 05. Important toxicities include stomatitis and ocular effects. ascopost.com/news/june-2025…

On June 23, 2025, the FDA granted accelerated approval to datopotamab deruxtecan-dlnk for adults with locally advanced or metastatic EGFR-mutated non-small cell #LungCancer ( #NSCLC ) who have previously received EGFR-directed therapy and platinum-based chemotherapy.